News Report | September 23, 2018
Polypharmacy Therapy For Schizophrenia Increases Risk For Type 2 Diabetes
Those health care consumers with schizophrenia who take a combination of three or more different psychotropic medications have an increased risk for type-2 diabetes. This group had a 1.81 odds ratio of developing type 2 diabetes, compared to those who received monotherapy with first-generation antipsychotics (FGA).
These findings were reported in "Combination Therapy As A Potential Risk Factor For The Development Of Type 2 Diabetes In Patients With Schizophrenia: The GOMAP Study" by Vasiliki Mamakou, Sophie Hackinger, Eleni Zengini, Evgenia Tsompanaki, et al. The researchers conducted a case-control Genetic Overlap between Metabolic and Psychiatric disease (GOMAP . . .